A phase I/II trial of weekly nab‐paclitaxel for pretreated non‐small‐cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement

AIM: We investigated the efficacy, safety and optimal schedule of nanoparticle albumin‐bound paclitaxel monotherapy as second‐ or third‐line treatment for non‐small‐cell lung cancer patients without epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement. METHODS: Pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Harada, Daijiro, Kozuki, Toshiyuki, Nogami, Naoyuki, Bessho, Akihiro, Hosokawa, Shinobu, Fukamatsu, Nobuaki, Hotta, Katsuyuki, Ohashi, Kadoaki, Kubo, Toshio, Yoshioka, Hiroshige, Yokoyama, Toshihide, Sone, Naoyuki, Kuyama, Shoichi, Kudo, Kenichiro, Yasugi, Masayuki, Takigawa, Nagio, Oze, Isao, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849786/
https://www.ncbi.nlm.nih.gov/pubmed/30938103
http://dx.doi.org/10.1111/ajco.13147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849786/
https://www.ncbi.nlm.nih.gov/pubmed/30938103
http://dx.doi.org/10.1111/ajco.13147

Ejemplares similares